181 related articles for article (PubMed ID: 35273656)
21. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
22. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
23. [Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspension array technology].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li DR; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Oct; 51(10):765-772. PubMed ID: 27788745
[No Abstract] [Full Text] [Related]
24. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract][Full Text] [Related]
25. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
26. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
27. Autoantibody signature for the serologic detection of ovarian cancer.
Anderson KS; Cramer DW; Sibani S; Wallstrom G; Wong J; Park J; Qiu J; Vitonis A; LaBaer J
J Proteome Res; 2015 Jan; 14(1):578-86. PubMed ID: 25365139
[TBL] [Abstract][Full Text] [Related]
28. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
29. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer detection by DNA methylation in cervical scrapings.
Wu TI; Huang RL; Su PH; Mao SP; Wu CH; Lai HC
Clin Epigenetics; 2019 Nov; 11(1):166. PubMed ID: 31775891
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
32. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
33. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.
Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF
J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
35. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
36. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
37. Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.
Yang Q; Qin J; Sun G; Qiu C; Jiang D; Ye H; Wang X; Dai L; Zhu J; Wang P; Zhang J
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00284. PubMed ID: 33346593
[TBL] [Abstract][Full Text] [Related]
38. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
[TBL] [Abstract][Full Text] [Related]
39. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.
Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L
Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809
[TBL] [Abstract][Full Text] [Related]
40. Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment.
Shen ZY; Shen AJ; Yang SL; Wu MF
Ultrasound Q; 2019 Mar; 35(1):45-53. PubMed ID: 30672869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
